Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway

Cellular Physiology and Biochemistry

Volumn 37, Issue 2, 2015, Pages 816-824

  Xia, Chen ^a   Bai, Xupeng ^a   Hou, Xiangyu ^a   Gou, Xiaoli ^a   Wang, Yongtao ^a   Zeng, Hang ^a   Huang, Min ^a   Jin, Jing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Cryptotanshinone; Lung cancer; Nrf2

Indexed keywords

CISPLATIN; CRYPTOTANSHINONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN; PHENANTHRENE DERIVATIVE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIZATION; FLOW CYTOMETRY; GCLC GENE; GCLM GENE; GENE; GENE EXPRESSION; GENE SILENCING; HO 1 GENE; HUMAN; HUMAN CELL; IC50; MRP1 GENE; NQO1 GENE; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2; PHENANTHRENES; SIGNAL TRANSDUCTION;

EID: 84941553293     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430398     Document Type: Article

References (21)

1. Tian Z, Yao G, Song H, Zhou Y, Geng J: IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. Cell Physiol Biochem 2014;34:1578-1588.
2. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320.
3. Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li X, Yin Z, Liang H: Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem 2014;33:1162-1175.
4. Suzuki T, Motohashi H, Yamamoto M: Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 2013;34:340-346.
5. Matuszcak C, Haier J, Hummel R, Lindner K: MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014;20:13658-13666.
6. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236:313-322.
7. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD: Nrf2-and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 2008;106:319-328.
8. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-1243.
9. Hayes JD, McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-188.
10. Chen W, Lu Y, Chen G, Huang S: Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anticancer Agents Med Chem 2013;13:979-987.
11. Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, Shen T, Liu Z, Lu Y, Huang S: Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila) 2010;3:1015-1025.
12. Park EJ, Zhao YZ, Kim YC, Sohn DH: Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo. Food Chem Toxicol 2009;47:2742-2748.
13. Chen L, Wang HJ, Xie W, Yao Y, Zhang YS, Wang H: Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Mol Med Rep 2014;9:2447-2452.
14. Pan Y, Bi HC, Zhong GP, Chen X, Zuo Z, Zhao LZ, Gu LQ, Liu PQ, Huang ZY, Zhou SF, Huang M: Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica 2008;38:382-398.
15. Li MH, Cha YN, Surh YJ: Peroxynitrite induces HO-1 expression via PI3K/Akt-dependent activation of NFE2-related factor 2 in PC12 cells. Free Radic Biol Med 2006;41:1079-1091.
16. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-7984.
17. Ohnuma T, Matsumoto T, Itoi A, Kawana A, Nishiyama T, Ogura K, Hiratsuka A: Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract. Biochem Biophys Res Commun 2011;413:623-629.
18. Gao AM, Ke ZP, Shi F, Sun GC, Chen H: Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact 2013;206:100-108.
19. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD: Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 2011;108:1433-1438.
20. Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, Schreiber S, Schafer H: Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 2013;32:4825-4835.
21. Yamadori T, Ishii Y, Homma S, Morishima Y, Kurishima K, Itoh K, Yamamoto M, Minami Y, Noguchi M, Hizawa N: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 2012;31:4768-4777.